Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Sana Biotechnology Inc (SANA) vs State Street Real Estate Select Sector SPDR ETF (XLRE) Price & Performance

Sana Biotechnology IncTrade
State Street Real Estate Select Sector SPDR ETFTrade

Price performance (Past 24H)

Key statistics

Sana Biotechnology Inc vs State Street Real Estate Select Sector SPDR ETF — how do they compare? Sana Biotechnology Inc trades at $3.24 (market cap $1.03B), while State Street Real Estate Select Sector SPDR ETF trades at $43.42. The key difference: State Street Real Estate Select Sector SPDR ETF is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals.

SANAXLRE
Market Cap
$1.03B
Sector
HealthSector/Thematic
52-Week High
$5.92$46.01
52-Week Low
$2.68$40.01
Enterprise Value
$946.04M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Sana Biotechnology Inc

SANA Biotechnology trades at $3.45, down 10.39% in the past 24 hours, reflecting bearish technical signals and negative profitability. The company reported a net loss of $244.17 million for 2025, with a price-to-book ratio of 6.68. Recent news includes investor conference presentations and a peer-reviewed publication in The New England Journal of Medicine highlighting clinical data.

Despite analyst consensus favoring a 'Buy' rating (81.82% of 11 analysts), the stock faces significant risks from negative cash flows, high losses, and potential fiduciary concerns. Upside hinges on successful clinical developments and improved financial performance, but current fundamentals suggest caution for investors.

State Street Real Estate Select Sector SPDR ETF

XLRE trades at $43.9, down 0.05% with a bearish technical signal from moving averages. The ETF shows neutral oscillator readings, with RSI near oversold levels. Recent news highlights real estate's resilience amid inflation, though some analysts warn of underperformance versus AI-focused alternatives. Dividend safety remains a focus, with a future dividend scheduled for June 2026.

Outlook is mixed; real estate offers diversification and income potential, but high interest rates and sector rotation pose risks. Investors should weigh XLRE's low expense ratio and U.S. focus against macroeconomic headwinds. Sentiment is cautious, with technical weakness suggesting near-term pressure.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Sana Biotechnology Inc

Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.

Read more on SANA

About State Street Real Estate Select Sector SPDR ETF

XLRE tracks the Real Estate Select Sector Index, providing exposure to S&P 500 real estate companies. It focuses on equity REITs across residential, industrial, and healthcare sub-sectors, with top holdings like Welltower, Prologis, and American Tower.

Read more on XLRE